Clinical trial

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

NCT05740943

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2023-03-15

PhasePHASE2

Study timeline

Study start (actual)2023-03-15Date precision: day

Registry last updated2026-01-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage III NSCLCunresolved

Surgeryunresolved

Interventions

LorlatinibDRUG · verified · RxNorm: lorlatinib

Sponsors & collaborators

Guangdong Provincial People's Hospitallead sponsor

Guangzhou No.12 People's Hospitalcollaborator

Peking Union Medical College Hospitalcollaborator

Second Xiangya Hospital of Central South Universitycollaborator

Mapped research locations

GuangzhouGuangdong, China2 ChangshaHunan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05740943 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.